Table 1.
Demographics and clinical characteristics of EOC patients.
| Variables | Control group (n = 574) |
CIT group (n = 72) |
p value* |
|---|---|---|---|
| Age (years) | 51.41 ± 10.82 | 50.62 ± 11.31 | 0.761 |
| CA125 (mean ± SD) | 2395.88 ± 5386.18 | 2448.2 ± 5033.1 | 0.935 |
| Pathologic grade | 0.376 | ||
| Well | 23 | 3 | |
| Moderate | 64 | 13 | |
| Poor | 364 | 46 | |
| missing cases | 123 | 10 | |
| FIGO tumor stage | 0.99 | ||
| Ⅰ/Ⅱ | 97 | 14 | |
| Ⅲ/Ⅳ | 466 | 58 | |
| missing data | 11 | 0 | |
| Histopathology | 0.244 | ||
| Serous carcinoma | 498 | 59 | |
| Mucinous carcinoma | 15 | 2 | |
| Clear cell carcinoma | 10 | 3 | |
| Endometrioid carcinoma | 20 | 3 | |
| Unspecified type | 31 | 5 | |
| Pelvic lymph node metastasis | 0.160 | ||
| Yes | 105 | 21 | |
| No | 163 | 20 | |
| missing data | 306 | 31 | |
| Abdominal aorta lymph node metastasis | 0.203 | ||
| Yes | 99 | 14 | |
| No | 91 | 7 | |
| missing data | 384 | 51 | |
|
Chemotherapy# CBP/CAP TP/TC Other Residual disease |
67 459 48 |
6 64 2 |
0.147 0.527 |
| < 1cm | 354 | 49 | |
| ≥ 1cm | 87 | 8 | |
| missing data | 133 | 15 |
*, Chi-Squared Tests;
#, CBP: Cyclophosphoramide + bleomycin + Cisplatin; CAP: Cyclophosphoramide + deoxymycin + Cisplatin; TP: paclitaxel + Cisplatin; TC: paclitaxel + Carborplatin.